$1.66
0.60%
Nasdaq, Sep 29, 04:00 pm EDT. Closed.
ISIN
US64132R1077
Symbol
MTVA

NeuroBo Pharmaceuticals Inc Stock price

$1.66
-0.06 3.49% 1M
+0.49 41.88% 6M
-6.76 80.29% YTD
-8.70 83.97% 1Y
-40.23 96.04% 3Y
-9,739.94 99.98% 5Y
-745,798.34 100.00% 10Y
-607,198.34 100.00% 20Y
Nasdaq, Closing price Tue, Sep 29 2026
-0.01 0.60%
ISIN
US64132R1077
Symbol
MTVA
Industry

Is NeuroBo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$11.0m
Enterprise Value
$-1.6m
Net debt
positive
Cash
$12.6m
Shares outstanding
6.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
1.6
Financial Health
Equity Ratio
48.0%
Return on Equity
-243.3%
ROCE
-215.8%
ROIC
678.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-14.9m
EBIT
$-14.9m
Net Income
$-14.5m
Free Cash Flow
$-15.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
25.6%
EBIT
25.5%
Net Income
21.8%
Free Cash Flow
16.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-2.4
Short interest
3.8%
Employees
8
Rev per Employee
$0.0

NeuroBo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

Buy
88%
Hold
13%

Financial data from NeuroBo Pharmaceuticals Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.18 7.18
6% 6%
-
- Research and Development Expense 7.85 7.85
41% 41%
-
-15 -15
26% 26%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -15 -15
25% 25%
-
Net Profit -14 -14
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about NeuroBo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroBo Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
●
21 days ago
Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced results fr...
Neutral
PRNewsWire
●
about 2 months ago
All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fourth Quarter of 2026 CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- MetaVia Inc.  (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for th...
Neutral
PRNewsWire
●
3 months ago
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 c...
More NeuroBo Pharmaceuticals Inc News

Company Profile

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

Head office United States
CEO Mr. Kim
Employees 8
Founded 2014
Website metaviatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today